These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16938718)

  • 1. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease.
    Vizoso FJ; González LO; Corte MD; Corte MG; Bongera M; Martínez A; Martín A; Andicoechea A; Gava RR
    Scand J Gastroenterol; 2006 Sep; 41(9):1050-5. PubMed ID: 16938718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease.
    Palatka K; Serfozo Z; Veréb Z; Hargitay Z; Lontay B; Erdodi F; Bánfalvi G; Nemes Z; Udvardy M; Altorjay I
    Scand J Gastroenterol; 2005 Jun; 40(6):670-80. PubMed ID: 16036527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease.
    Kruidenier L; Kuiper I; van Duijn W; Marklund SL; van Hogezand RA; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):7-16. PubMed ID: 12950012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease.
    Kruidenier L; Kuiper I; Van Duijn W; Mieremet-Ooms MA; van Hogezand RA; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):17-27. PubMed ID: 12950013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease.
    Andoh A; Deguchi Y; Inatomi O; Yagi Y; Bamba S; Tsujikawa T; Fujiyama Y
    Oncol Rep; 2006 Jul; 16(1):103-7. PubMed ID: 16786130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.
    Olsen T; Rismo R; Cui G; Goll R; Christiansen I; Florholmen J
    Cytokine; 2011 Dec; 56(3):633-40. PubMed ID: 21945121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype.
    Meijer MJ; Mieremet-Ooms MA; van der Zon AM; van Duijn W; van Hogezand RA; Sier CF; Hommes DW; Lamers CB; Verspaget HW
    Dig Liver Dis; 2007 Aug; 39(8):733-9. PubMed ID: 17602907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.
    Gao Q; Meijer MJ; Kubben FJ; Sier CF; Kruidenier L; van Duijn W; van den Berg M; van Hogezand RA; Lamers CB; Verspaget HW
    Dig Liver Dis; 2005 Aug; 37(8):584-92. PubMed ID: 15869913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease.
    Bernstein CN; Robert ME; Eysselein VE
    Am J Gastroenterol; 1993 Jun; 88(6):908-13. PubMed ID: 7684884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice.
    Bamba S; Lee CY; Brittan M; Preston SL; Direkze NC; Poulsom R; Alison MR; Wright NA; Otto WR
    J Pathol; 2006 Jun; 209(2):265-73. PubMed ID: 16550633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
    Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
    Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.
    Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R
    J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry.
    ter Beek WP; Biemond I; Muller ES; van den Berg M; Lamers CB
    Neuropeptides; 2007 Oct; 41(5):301-6. PubMed ID: 17602742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease.
    Fitzpatrick LR; Small JS; Poritz LS; McKenna KJ; Koltun WA
    Dis Colon Rectum; 2007 Mar; 50(3):337-48; discussion 348-50. PubMed ID: 17160513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.